Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
NEW YORK (Reuters Health) – The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung…
NEW YORK (Reuters Health) – Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional…
NEW YORK (Reuters Health) – After first-line treatment with bevacizumab plus interferon-alpha2a, subsequent therapy with tyrosine kinase inhibitors (TKIs) improves survival in patients with metastatic renal cell carcinoma,…
NEW YORK (Reuters Health) – High-dose chemo followed by autologous stem-cell transplantation achieves good results in patients with relapsed Hodgkin’s lymphoma, and outcomes are not improved by additional…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
Jacob G. Robison, MD, Professor of Vascular Surgery, Medical University of South Carolina, discusses reversal of flow, a technique where particles that occur at the time of balloon…
Jacob G. Robison, MD, Professor of Vascular Surgery, Medical University of South Carolina, discusses abdominal aortic aneurysm repair using stent grafts. These devices must be used in an…
NEW YORK (Reuters Health) – For patients with multiple myeloma who are not eligible for autologous stem-cell transplantation, a four-drug combination regimen is promising. Adding thalidomide to bortezomib-melphalan-prednisone,…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
